# AC Immune SA (ACIU)

Source: https://www.quantisnow.com/company/ACIU
Generated: 2026-11-14T10:38:17.464Z

- Ticker: ACIU
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2016
- SEC CIK: 0001651625
- Website: acimmune.com

## About

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

## Latest ACIU news and filings

- 2026-11-11 12:00 UTC [Conference Announcement] [AC Immune to Present at Jefferies Global Healthcare Conference 2026](https://www.quantisnow.com/insight/ac-immune-to-present-at-jefferies-global-healthcare-conference-2026-6785123)
- 2026-11-04 12:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by AC Immune SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ac-immune-sa-6771237)
- 2026-11-04 12:00 UTC [AC Immune Third Quarter 2026 Financial and Corporate Update](https://www.quantisnow.com/insight/ac-immune-third-quarter-2026-financial-and-corporate-update-6771173)
- 2026-10-09 21:22 UTC [SEC Form 3] [Amendment: SEC Form 3/A filed by AC Immune SA](https://www.quantisnow.com/insight/amendment-sec-form-3a-filed-by-ac-immune-sa-6743250)
- 2026-10-09 12:08 UTC [SEC Form 3] [SEC Form 3 filed by AC Immune SA](https://www.quantisnow.com/insight/sec-form-3-filed-by-ac-immune-sa-6742417)
- 2026-10-02 12:02 UTC [SEC Form 6-K] [SEC Form 6-K filed by AC Immune SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ac-immune-sa-6733509)
- 2026-09-23 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by AC Immune SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ac-immune-sa-6723575)
- 2026-09-23 11:00 UTC [Earnings Date] [AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104](https://www.quantisnow.com/insight/ac-immune-reports-positive-safety-immunogenicity-at-week-100-in-part-6723551)
- 2026-09-03 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by AC Immune SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ac-immune-sa-6704150)
- 2026-08-20 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by AC Immune SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ac-immune-sa-6689323)
- 2026-08-11 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by AC Immune SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ac-immune-sa-6674852)
- 2026-08-05 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by AC Immune SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ac-immune-sa-6663864)
- 2026-08-05 11:00 UTC [Leadership Update] [AC Immune First Half 2026 Financial and Corporate Update](https://www.quantisnow.com/insight/ac-immune-first-half-2026-financial-and-corporate-update-6663803)
- 2026-07-07 11:00 UTC [AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026](https://www.quantisnow.com/insight/ac-immune-to-showcase-neurodegenerative-disease-pipeline-with-three-presentations-6629347)
- 2026-06-30 13:03 UTC [SEC Form 6-K] [SEC Form 6-K filed by AC Immune SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ac-immune-sa-6620292)
- 2026-06-30 11:00 UTC [AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease](https://www.quantisnow.com/insight/ac-immune-reports-interim-12-month-data-from-phase-1b2-abate-6619891)
- 2026-06-15 11:10 UTC [SEC Form 4] [Director Twyman Roy Ervin was granted 16,568 units of Common Share, increasing direct ownership by 22% to 92,556 units (SEC Form 4)](https://www.quantisnow.com/insight/director-twyman-roy-ervin-was-granted-16568-units-of-common-6601777)
- 2026-06-15 10:59 UTC [SEC Form 4] [Director Aguiar-Lucander Renee was granted 16,568 units of Common Share, increasing direct ownership by 48% to 51,136 units (SEC Form 4)](https://www.quantisnow.com/insight/director-aguiar-lucander-renee-was-granted-16568-units-of-common-share-6601728)
- 2026-06-15 10:50 UTC [SEC Form 4] [Interim CEO Zuegel Martin was granted 33,136 units of Common Share, increasing direct ownership by 87% to 71,408 units (SEC Form 4)](https://www.quantisnow.com/insight/interim-ceo-zuegel-martin-was-granted-33136-units-of-common-6601723)
- 2026-06-15 10:40 UTC [SEC Form 4] [Director Buetler Monika was granted 17,751 units of Common Share, increasing direct ownership by 33% to 71,656 units (SEC Form 4)](https://www.quantisnow.com/insight/director-buetler-monika-was-granted-17751-units-of-common-share-6601710)
- 2026-06-15 10:31 UTC [SEC Form 4] [Director June Carl Howard was granted 16,568 units of Common Share, increasing direct ownership by 32% to 67,556 units (SEC Form 4)](https://www.quantisnow.com/insight/director-june-carl-howard-was-granted-16568-units-of-common-6601705)
- 2026-06-11 20:53 UTC [SEC Form 6-K] [SEC Form 6-K filed by AC Immune SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ac-immune-sa-6598968)
- 2026-06-11 11:15 UTC [SEC Form 6-K] [SEC Form 6-K filed by AC Immune SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ac-immune-sa-6598153)
- 2026-05-22 11:00 UTC [AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS](https://www.quantisnow.com/insight/ac-immune-presents-new-phase-1-data-indicating-higher-uptake-6568786)
- 2026-05-18 20:25 UTC [SEC Form 4] [Chief Executive Officer Pfeifer Andrea sold $27,935 worth of Common Share (10,000 units at $2.79), decreasing direct ownership by 0.26% to 3,820,288 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-pfeifer-andrea-sold-27935-worth-of-common-6560408)
- 2026-05-15 13:17 UTC [SEC Form 6-K] [SEC Form 6-K filed by AC Immune SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ac-immune-sa-6556134)
- 2026-05-12 12:13 UTC [SEC Form 6-K] [SEC Form 6-K filed by AC Immune SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ac-immune-sa-6546821)
- 2026-05-12 11:00 UTC [Leadership Update] [AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM](https://www.quantisnow.com/insight/ac-immune-announces-retirement-of-ceo-dr-andrea-pfeifer-at-6546511)
- 2026-04-30 11:09 UTC [SEC Form 6-K] [SEC Form 6-K filed by AC Immune SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ac-immune-sa-6522753)
- 2026-04-30 11:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by AC Immune SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ac-immune-sa-6522736)
- 2026-04-30 11:05 UTC [AC Immune First Quarter 2026 Financial and Corporate Updates](https://www.quantisnow.com/insight/ac-immune-first-quarter-2026-financial-and-corporate-updates-6522729)
- 2026-04-30 11:00 UTC [AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease](https://www.quantisnow.com/insight/ac-immune-initiates-final-cohort-in-ongoing-phase-1b2-abate-6522627)
- 2026-04-16 16:39 UTC [SEC Form 4] [Amendment: SEC Form 4 filed by Pfeifer Andrea](https://www.quantisnow.com/insight/amendment-sec-form-4-filed-by-pfeifer-andrea-6502779)
- 2026-04-16 15:10 UTC [SEC Form 4] [SEC Form 4 filed by Pfeifer Andrea](https://www.quantisnow.com/insight/sec-form-4-filed-by-pfeifer-andrea-6502727)
- 2026-04-07 11:33 UTC [SEC Form 6-K] [SEC Form 6-K filed by AC Immune SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ac-immune-sa-6490303)
- 2026-04-07 11:00 UTC [AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly](https://www.quantisnow.com/insight/ac-immune-announces-amendment-to-morphomer-tau-license-and-collaboration-6490201)
- 2026-04-01 20:51 UTC [SEC Form 3] [SEC Form 3 filed by new insider Zuegel Martin](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-zuegel-martin-6482448)
- 2026-03-20 15:59 UTC [SEC Form 3] [SEC Form 3 filed by new insider Donati Piergiorgio](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-donati-piergiorgio-6462911)
- 2026-03-18 17:09 UTC [SEC Form 3] [SEC Form 3 filed by new insider Roberts Christopher James](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-roberts-christopher-james-6456860)
- 2026-03-18 16:35 UTC [SEC Form 3] [SEC Form 3 filed by new insider Buetler Monika](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-buetler-monika-6456750)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ACIU
- Earnings history: https://www.quantisnow.com/earnings/ACIU
- Dividend history: https://www.quantisnow.com/dividends/ACIU
- Insider transactions: https://www.quantisnow.com/insiders/ACIU
- Options chain: https://www.quantisnow.com/options/ACIU
- SEC 8-K filings only: https://www.quantisnow.com/company/ACIU/8-k
- RSS and alerts for ACIU: https://www.quantisnow.com/docs/rss-feeds.md